Eloxx Pharmaceuticals, Inc. (ELOX)
ELOXNASDAQ-CMBiotechnology: Biological Products (No Diagnostic Substances)
$12.90
-0.5600 (-4.16%) today
At the close, Nov 10, 4:00 PM ET. After hours $12.91 +0.05%
- Market cap
- $52.07m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- $12.90 to $13.40
- 52-week range
- $8.20 to $23.40
- Average volume
- 26.6k
- Previous close
- $13.46
Analysts
5 coveringBuy5 buy, 0 hold, 0 sell
Targets a year out average $37.50, +190.7% from here
Earnings
Next report
Mar 2026
–
Jun 2026
–
estimate reported, and the surprise
Financials
| Quarter | Sep 2023 | Dec 2023 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$3.64m | -$4.03m | -$3.79m | -$4.45m |
| Net income | -$3.59m | -$2.89m | -$3.75m | -$4.50m |
News
8 latest- Eloxx Gains FDA Clearance For Exaluren Phase 2 Trial In Genetic Kidney Disease RTTNews · Oct 29, 2026
- Eloxx Pharmaceuticals Appoints Geno J. Germano to Board on October 19, 2026 and Announces Clinical UpdateFintel · Oct 22, 2026
- Eloxx Finalizes Phase 2 ADPKD Trial Design Following FDA Feedback; Appoints New CMO RTTNews · Oct 21, 2026
- Cantor Fitzgerald Initiates Coverage of Eloxx Pharmaceuticals at OverweightFintel · Oct 15, 2026
- Biotech Stocks At 52-Week Highs - ELOX, PRLD, ARGX, BOLD, CORT RTTNews · Aug 24, 2026
- Top Biotech Gainers: ELOX Clinical Progress, VOGX IPO Success, ARCT Pipeline Updates Drive Gains RTTNews · Aug 21, 2026
- Eloxx Q2 Loss Widens; Exaluren Phase 2b Trial Set To Begin In Q3 2026 RTTNews · Aug 21, 2026
- Eloxx Pharmaceuticals, Inc. Loss At -$4.50 Mln In Q2 RTTNews · Aug 12, 2026
The company
Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) is a clinical-stage biopharmaceutical company developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations to enable the production of full-length proteins. Eloxx's lead product candidate, exaluren, is being developed for the treatment of rare kidney diseases, including nonsense mutation Alport syndrome and nonsense mutation autosomal dominant polycystic kidney disease (ADPKD). Eloxx has also exclusively licensed its product candidate, ZKN-013, to Almirall, S.A., which is developing it for the treatment of rare dermatological diseases associated with nonsense mutations.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- eloxxpharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.